Human Anti-HA Recombinant Antibody (HPAB-M0100-YC)

Customer Review

There are currently no Customer reviews or questions for HPAB-M0100-YC. Click the button above to contact us or submit your feedback about this product.

James Thompson
20.Dec,23

Great for HA Studies

The Anti-HA Antibody has been excellent for our HA detection assays. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Emily Clark
15.May,22

Effective in Western Blots

We incorporated this antibody into our Western blot assays, and it has been a great addition. The specificity for HA is precise, consistently detecting the target protein with high clarity. The reliable performance has made it an essential tool in our research.

David Harris
07.Aug,21

Consistent and Reliable

This antibody has proven to be consistent and effective in our various assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for HA have been particularly beneficial.

Q&As

1. Is the anti-HA antibody suitable for use in Western blotting?

   A: Yes, the anti-HA antibody (HPAB-M0100-YC) is suitable for use in Western blotting. It provides specific binding to HA-tagged proteins, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-HA antibody?

   A: The recommended storage condition for the anti-HA antibody (HPAB-M0100-YC) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-HA antibody be used in immunoprecipitation assays?

   A: Yes, the anti-HA antibody (HPAB-M0100-YC) can be used in immunoprecipitation assays. It provides specific binding to HA-tagged proteins, enabling their successful precipitation from complex mixtures.

4. Is the anti-HA antibody effective in ELISA applications?

   A: Yes, the anti-HA antibody (HPAB-M0100-YC) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of HA-tagged proteins.

5. What is the optimal dilution for using the anti-HA antibody in immunofluorescence?

   A: The optimal dilution for using the anti-HA antibody (HPAB-M0100-YC) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Sautto, Giuseppe A., et al. "A computationally optimized broadly reactive antigen subtype-specific influenza vaccine strategy elicits unique potent broadly neutralizing antibodies against hemagglutinin." The Journal of Immunology 204.2 (2020): 375-385. https://doi.org/10.4049/jimmunol.1900379
   This study focuses on the development of a computationally optimized broadly reactive antigen (COBRA) subtype-specific influenza vaccine strategy. The research aimed to generate and evaluate the efficacy of a COBRA-based hemagglutinin (HA) immunogen in eliciting broadly neutralizing antibodies against multiple H1N1 influenza viral strains. Through the immunization of mice with the COBRA HA antigen, the study successfully identified monoclonal antibodies (mAbs) with broad hemagglutination inhibition (HAI) activity, capable of recognizing and neutralizing a diverse array of H1N1 strains, both seasonal and pandemic. The findings demonstrated that the COBRA HA vaccine elicited a robust and wide-ranging immune response, providing insights into the design of a more universally protective influenza vaccine.
   Creative Biolabs contributed to this study by providing several key monoclonal antibodies used for binding and functional studies, including HA stem-directed human mAbs CR6261, FI6 (Cat#: HPAB-M0100-YC), and F10. These antibodies were essential in the characterization of the immune response elicited by the COBRA HA vaccine. Specifically, they were used to evaluate the breadth and specificity of the antibody response, helping to identify mAbs with the desired broad reactivity and neutralizing capabilities. The reliable performance of these mAbs ensured accurate and reproducible results, supporting the study's goal of advancing the development of a next-generation influenza vaccine.
2. Abreu, Rodrigo B., et al. "IgA responses following recurrent influenza virus vaccination." Frontiers in immunology 11 (2020): 528797. https://doi.org/10.3389/fimmu.2020.00902
   This study investigates the IgA responses following recurrent influenza virus vaccination. Researchers administered the split inactivated influenza vaccine to young adults (18-34 years old) and elderly (65-85 years old) subjects for three consecutive seasons. They then profiled the serological IgA and IgG responses. The study aimed to understand the correlation between vaccine-induced IgA antibody titers and traditional immunological endpoints. The results showed that both young and elderly subjects developed specific IgA responses to the influenza vaccine, highlighting IgA as an important immune correlate during influenza vaccination.
   Creative Biolabs contributed to this study by providing the stem-directed monoclonal antibody CR6261 and FI6 (Cat#: HPAB-M0100-YC). These antibodies were used to validate the correct stem conformation of the chimeric HA protein through enzyme-linked immunosorbent assay (ELISA). The involvement of these antibodies was crucial in ensuring the accuracy and reliability of the HA protein structure, thereby supporting the study's evaluation of the serological IgA response to the influenza vaccine.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# HPAB-M0100-YC, RRID: AB_3111435)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Sautto, Giuseppe A., et al. "A Computationally Optimized Broadly Reactive Antigen Subtype–Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin." The Journal of Immunology (2019).

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "HA"

Select a product category from the dropdown menu below to view related products.